Related Experiment Video
Updated: Apr 18, 2026
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
Published on: June 13, 2018
A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells
Jlenia Guarnerio1, Luisa Riccardi1, Riccardo Taulli1
1Cancer Research Institute, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Unlabelled:
The regulatory factors governing adult mesenchymal stem cell (MSC) physiology and their tumorigenic potential are still largely unknown, which substantially delays the identification of effective therapeutic approaches for the treatment of aggressive and lethal forms of MSC-derived mesenchymal tumors, such as undifferentiated sarcomas. Here, we have developed a novel platform to screen and quickly identify genes and pathways responsible for adult MSC transformation, modeled undifferentiated sarcoma in vivo, and, ultimately, tested the efficacy of targeting the identified oncopathways. Importantly, by taking advantage of this new platform, we demonstrate the key role of an aberrant LRF-DLK1-SOX9 pathway in the pathogenesis of undifferentiated sarcoma, with important therapeutic implications.
Significance:
The paucity of therapeutic options for the treatment of sarcoma calls for a rapid and effective preclinical assessment of new therapeutic modalities. We have here developed a new platform to deconstruct the molecular genetics underlying the pathogenesis of sarcoma and to evaluate in vivo the efficacy of novel targeted therapies.
Insights
Researchers identified a new pathway crucial in undifferentiated sarcoma development. This discovery offers potential new therapeutic targets for aggressive mesenchymal tumors, improving treatment options.
Area of Science:
- Oncology
- Stem Cell Biology
- Molecular Genetics
Background:
- Regulatory factors controlling adult mesenchymal stem cell (MSC) physiology and tumorigenic potential remain largely unknown.
- This knowledge gap hinders the development of effective therapies for aggressive MSC-derived tumors like undifferentiated sarcomas.
Purpose of the Study:
- To develop a novel platform for screening genes and pathways involved in adult MSC transformation.
- To model undifferentiated sarcoma in vivo and evaluate targeted therapies for identified oncogenic pathways.
Main Methods:
- Development of a novel screening platform for MSC transformation.
- In vivo modeling of undifferentiated sarcoma.
- Testing therapeutic efficacy of targeting identified oncogenic pathways.
Main Results:
- Identification of a novel platform for rapid screening of MSC transformation.
- Successful in vivo modeling of undifferentiated sarcoma.
- Demonstration of the critical role of the LRF-DLK1-SOX9 pathway in undifferentiated sarcoma pathogenesis.
Conclusions:
- A new platform enables deconstruction of sarcoma molecular genetics and in vivo evaluation of targeted therapies.
- The LRF-DLK1-SOX9 pathway is a key player in undifferentiated sarcoma, presenting therapeutic implications.
More Related Videos
09:21Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
07:27Generation of Mesenchymal Stem Cells from Human Umbilical Cord Tissue and their Differentiation into the Skeletal Muscle Lineage
Published on: August 31, 2022
